AstaReal Technologies triples astaxanthin production capacity with new factory in Moses Lake, WA

MOSES LAKE, Wash., May 16, 2014 /PRNewswire/ -- AstaReal Technologies, Inc. grand opening ceremony for its new production facility in Moses Lake, Wash., was held May 14 and attended by Washington State Governor Jay Inslee, members of the state legislature, the director of the Department of Commerce, and officials and community leaders from Grant County and the City of Moses Lake.  Approximately 200 people, comprised of civic and business leaders from the local community, as well as guests from abroad, attended the ceremony.  The new 59,000 sq. ft. factory will produce natural astaxanthin and is expected to begin production by July 2014, initially employing approximately 45 people.

The AstaReal Group has been producing natural astaxanthin in Gustavsberg, Sweden, and decided to build an additional factory in response to increased global demand. The new factory will have more than double the production capacity of the existing Swedish facility and will more than triple the AstaReal Groups' total production capacity. The increased capacity will allow AstaReal to offer a stable supply of natural astaxanthin to its customers in the United States and around the world.  The factory site in Moses Lake has ample space for further expansion.

The City of Moses Lake in Grant County was chosen after a global search and is a perfect match for AstaReal Technologies' new factory.  Moses Lake offers a stable supply of pure water and renewable electrical energy, two resources that are critical to the success of the new facility.

"AstaReal is honored to be a community member of Moses Lake, Grant County and Washington State, and expects the community will experience significant growth and development which it hopes to contribute to," said Mitsunori Nishida, president and CEO of Fuji Chemical Industry.

Numerous clinical studies conducted in humans have assessed astaxanthin's safety, bioavailability, and clinical aspects relevant to oxidative stress and the inflammatory process.  Research shows that astaxanthin may be effective in helping to maintain cardiovascular health as well as supporting the body in its fight against metabolic syndrome conditions.  The number of studies exploring astaxanthin's potential benefits has greatly increased during the last decade, to include research areas such as eye health, hypertension, diabetes, and nonalcoholic steatohepatitis (NASH).

"We see the 21st century as the era of anti-aging," said Nishida.  "We believe that natural astaxanthin will play a key role in the advancement of anti-aging and lifestyle disease research." 

AstaReal Technologies' parent company Fuji Chemical Industry Co., Ltd. was established in 1946, and is a global pharmaceutical company focusing on three main business areas including the production and sales of high performance pharmaceutical products, synthesis and manufacturing of active pharmaceutical ingredients and bulk products, and the production and sales of nutraceuticals. The Fuji Group currently sells its products in over 20 countries, and FY2013 sales exceeded 10 billion JPY. Fuji uses AstaREAL® as the global brand name for its natural astaxanthin business.

For more information contact AstaReal, Inc. at [email protected] or by phone at 609-386-3030. AstaReal is located at 3 Terri Lane, #12, Burlington, NJ 08016.

For more information contact:
Sheldon Baker
Baker Dillon Group
559.325.7191
[email protected]

Photo - http://photos.prnewswire.com/prnh/20140516/88296

SOURCE AstaReal Technologies, Inc.